WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group (REPL), Inc. , a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced ...
When the FDA turns down a drug application, it has historically been up to the drug company to reveal it. These FDA complete response letters, or CRLs, have not been considered public documents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback